Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: a comparative animal study.

The effective clinical use of the anticancer drug 5-fluorouracil (5-FU) requires the non-invasive assessment of its transport and metabolism, particularly in the tumor and the liver, where the drug is catabolized to alpha-fluoro-beta-alanine (FBAL). In this study, the potentials and limitations of dynamic 18F PET and metabolic 19F MRI examinations for noninvasive 5-FU monitoring were investigated in ACI and Buffalo rats with transplanted MH3924A and TC5123 Morris hepatomas, respectively. Selective 5-[19F]FU and [19F]FBAL MR images were acquired 5 and 70 min after 5-FU injection using a CHESS MRI sequence. After administration of 5-[18F]FU, the kinetics of the regional 5-[18F]FU uptake were measured by dynamic PET scanning over 120 min. To allow a comparison between PET and MRI data, standardized uptake values (SUV) were computed at the same points in time. The TC5123 hepatoma showed a significantly (p < 0.002) higher mean SUV at 5 and 70 min post-5-FU injection than the MH3924A cell lines, whereas there were no significant differences between the mean SUV measured in the liver of both animal populations. In contrast to the PET data, no significant differences in the mean 5-[19F]FU and [19F]FBAL MR signal values in the tumor of both models were observed. The MR images, however, yielded the additional information that 5-FU is converted to FBAL only in the liver and not in the hepatomas.

[1]  J. Griffiths,et al.  5-fluorouracil metabolism monitored in vivo by 19F NMR. , 1984, British Journal of Cancer.

[2]  J. Delforge,et al.  Contribution of Positron Emission Tomography to Pharmacokinetic Studies , 1991 .

[3]  W Wolf,et al.  Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. , 1987, Magnetic resonance imaging.

[4]  V. R. McCready,et al.  Comparison of 5-fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo 19F magnetic resonance spectroscopy. , 1990, The British journal of radiology.

[5]  F. Oberdorfer,et al.  Preparation of 18F‐labelled 5‐fluorouracil of very high purity , 1989 .

[6]  T. Ng,et al.  19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. , 1991, Cancer research.

[7]  Peter Bachert,et al.  Original contributionSelective 19F MR imaging of 5-fluorouracil and α-fluoro-β-alanine , 1993 .

[8]  Gordon L. Amidon,et al.  Pharmacokinetics of Drugs , 1994, Handbook of Experimental Pharmacology.

[9]  W. Ritschel.  Handbook of basic pharmacokinetics , 1976 .

[10]  G. van Kaick,et al.  Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  J. Griffiths,et al.  Detection of differential sensitivity to 5‐fluorouracil in ehrlich ascites tumour cells by 19F NMR spectroscopy , 1991, NMR in biomedicine.

[12]  A. Fischman,et al.  In Vivo Imaging in Drug Discovery and Design , 1994 .

[13]  R. Dedrick,et al.  Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes , 1980, Clinical pharmacology and therapeutics.

[14]  W. J. Lorenz,et al.  Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. , 1990, Radiology.

[15]  C. Allegra,et al.  Preclinical and clinical aspects of biomodulation of 5-fluorouracil. , 1994, Cancer treatment reviews.

[16]  N. Kemeny.  The systemic chemotherapy of hepatic metastases. , 1983, Seminars in oncology.

[17]  G Brix,et al.  Selective 19F MR imaging of 5-fluorouracil and alpha-fluoro-beta-alanine. , 1993, Magnetic resonance imaging.

[18]  Robert M. Lewitt,et al.  Accelerated Iterative Reconstruction for Positron Emission Tomography Based on the EM Algorithm for Maximum Likelihood Estimation , 1986, IEEE Transactions on Medical Imaging.

[19]  W. Wolf,et al.  In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. , 1991, Cancer research.

[20]  W. Sadee.  Pharmacokinetics of Anticancer Drugs , 1976 .

[21]  Gunnar Brix,et al.  PET Image Reconstruction for Pharmacokinetic Modeling of 5-[18F]Fluorouracil in Liver Tumors , 1995 .

[22]  B. Chabner.  Pharmacologic principles of cancer treatment , 1982 .

[23]  W. J. Lorenz,et al.  Mapping the biodistribution and catabolism of 5‐fluorouracil in tumor‐bearing rats by chemical‐shift selective 19F MR imaging , 1995, Magnetic resonance in medicine.

[24]  L. Shepp,et al.  Maximum Likelihood Reconstruction for Emission Tomography , 1983, IEEE Transactions on Medical Imaging.

[25]  D. Casciato.  Manual of Clinical Oncology , 1995 .

[26]  R Mezrich,et al.  A perspective on K-space. , 1995, Radiology.

[27]  W. Foye.  Cancer chemotherapeutic agents , 1995 .

[28]  H. Pinedo,et al.  Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Heidelberger,et al.  Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.

[30]  J. Mazziotta,et al.  Positron emission tomography and autoradiography: Principles and applications for the brain and heart , 1985 .

[31]  W. J. Lorenz,et al.  Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. , 1994, Magnetic resonance imaging.

[32]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  P. Barker,et al.  Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Semmler,et al.  Kinetic modeling of in vivo—nuclear magnetic resonance spectroscopy data: 5–Fluorouracil in liver and liver tumors , 1991, Clinical pharmacology and therapeutics.

[35]  T. Ng,et al.  Multinuclear MR investigation of the metabolic response of the murine RIF‐1 tumor to 5‐fluorouracil chemotherapy , 1991, Magnetic resonance in medicine.

[36]  Sibylle Ziegler,et al.  Scatter correction in the transaxial slices of a whole-body positron emission tomograph , 1993 .

[37]  C. Heidelberger.  On the rational development of a new drug: the example of the fluorinated pyrimidines. , 1981, Cancer treatment reports.

[38]  W. J. Lorenz,et al.  Drug-specific /sup 19/F NMR and dynamic /sup 18/F PET imaging of the cytostatic agent 5-fluorouracil , 1994 .

[39]  J. Griffiths,et al.  19F MRS studies of fluoropyrimidine chemotherapy. A review , 1989, NMR in biomedicine.

[40]  L. Strauss,et al.  Perfusion of colorectal liver metastases and uptake of fluorouracil assessed by H2(15)O and [18F]uracil positron emission tomography (PET). , 1993, European journal of cancer.

[41]  J. Griffiths,et al.  In vivo 19F NMR spectroscopy of the antimetabolite 5-fluorouracil and its analogues. An assessment of drug metabolism. , 1990, Biochemical pharmacology.

[42]  R. Herrmann,et al.  Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. , 1988, Cancer research.

[43]  C. Myers.  The pharmacology of the fluoropyrimidines. , 1981, Pharmacological reviews.

[44]  H. Bergmann,et al.  Radioactive Isotopes in Clinical Medicine and Research , 1995 .

[45]  C. Presant,et al.  Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Morris.  Studies on the development, biochemistry, and biology of experimental hepatomas. , 1965, Advances in cancer research.